Characterization of Full‐Length Antibody Complexes Through HDX‐Mass Spectrometry Coupled With NMR Spectroscopy: New Insight Into Avelumab/PD‐L1 Interaction
Aug 2026· Angewandte Chemie· Vol 65· 0 citations· 90 references
Medicine
TL;DR
An integration of solid‐state nuclear magnetic resonance (SSNMR) and hydrogen–deuterium exchange mass spectrometry (HDX‐MS) is introduced to explore the interaction between Avelumab and the programmed cell death‐ligand 1 (PD‐L1).
Abstract
ABSTRACT Recombinant biomacromolecules have significantly transformed pharmaceuticals, in particular monoclonal antibodies (mAbs) that target key areas in oncology, immunology, inflammation, and neurodegenerative diseases. Developing biotherapeutics requires a detailed understanding of their biological properties. This, in turn, brings about the importance of characterizing higher‐order protein structures at each stage, from production to patient. The flexibility and size of the mAbs often prevent achieving atomic‐level structural information in the pharmaceutical formulation by traditional methods. In this study, we introduce an integration of solid‐state nuclear magnetic resonance (SSNMR) and hydrogen–deuterium exchange mass spectrometry (HDX‐MS) to explore the interaction between Avelumab and the programmed cell death‐ligand 1 (PD‐L1). With this approach, we were able to obtain epitope (by both NMR and HDX) and paratope mapping (by HDX), together with a detailed characterization of the structural rearrangements arising upon binding. This methodology provides both mechanistic and structural insights important for the design and optimization of biotherapeutics.
The biological activity and stability of monoclonal antibodies (mAbs) can be potentially compromised by chemical and conformational changes and assessing the structural integrity of mAbs is therefore a critical task in biopharmaceutical development. Monitoring higher-order structure (HOS) in formulated mAbs remains a...
M. Gairí, M. González, Victor A. Beaumont et al.· Analytical Chemistry· 0 citations
Antibody–drug conjugates (ADCs) are biotherapeutics that are structurally heterogeneous due to the way each ADC is formed. Therefore, complementary analytical approaches need to be used in order to achieve a complete characterization of all aspects of the structure of these biotherapeutics. This project created a multi...
HeeJae Yoo, Abhik Mojumdar, Minsun Kim et al.· Journal of Analytical Scienc...· 0 citations
Radioligands targeting fibroblast activation protein alpha (FAP) are promising tools for cancer diagnosis and therapy. However, the molecular binding mode of clinically established UAMC-1110-derived ligands such as FAPI-46 remains insufficiently characterized. To simplify synthesis while preserving key binding properti...
Chao Zhang, J. Gerhards, Lara Scharbert et al.· bioRxiv· 0 citations
Understanding the interactions between fluorinated anticancer drugs (FACDs) and lipid assemblies is fundamental to the development of next‐generation therapeutics with improved efficacy and pharmacological safety. To this end, atomistic‐level interactions, in terms of binding and dynamics of FACDs, such as 5‐fluoro...
Jyothirmai Pujari, B. V. N. Phani Kumar· ChemistrySelect· 0 citations
This review summarizes recent advances in nanobody engineering for NMR studies, including the synthetic nanobodies, highlights the nanobodies' role in overcoming size and stability limitations, and discusses future directions for integrating nanobodies into emerging NMR methodologies, with an emphasis on protein dynami...